Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763248 | 0.86 | SCN9A (0.58) | SCN9ASCN5AKCNH2KCNA5 | |
| SCHEMBL3755617 | 0.85 | KCNA5 (0.68) | P2RX7PRMT5WDR77SCN9ASCN5A | |
| SCHEMBL3756795 | 0.85 | P2RX7 (0.64) | P2RX7PRMT5WDR77ALDH1A1POLB | |
| SCHEMBL3750338 | 0.84 | P2RX7 (0.63) | P2RX7PRMT5WDR77ALDH1A1POLB | |
| SCHEMBL3750467 | 0.83 | P2RX7 (0.59) | P2RX7PRMT5WDR77SCN9ASCN5A | |
| SCHEMBL3751258 | 0.82 | P2RX7 (0.60) | P2RX7PRMT5WDR77POLBKCNA5 | |
| SCHEMBL3750209 | 0.82 | P2RX7 (0.60) | P2RX7PRMT5WDR77SCN9ASCN5A | |
| SCHEMBL3762599 | 0.81 | ALDH1A1 (0.66) | P2RX7PRMT5WDR77SCN9ASCN5A | |
| SCHEMBL3758555 | 0.81 | P2RX7 (0.59) | P2RX7PRMT5WDR77SCN9ASCN5A | |
| SCHEMBL3750441 | 0.80 | SCN9A (0.61) | SCN9ASCN5AKCNH2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | P2RX7 1839/4885PRMT5 1341/4885WDR77 2402/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | P2RX7 1138/4885PRMT5 683/4885WDR77 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.